Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...
Barclays raised the firm’s price target on Chart Industries (GTLS) to $165 from $145 and keeps an Equal Weight rating on the shares. Despite ...
The greater degree of control over integrating its equipment and processes also improved its pricing power, margins, and customer switching costs. Chart's 2025 expectations call for $4.75 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results